Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions.

T cell T cell receptor (TCR) cell signaling immunology immunotherapy inhibition mechanism kinase-substrate relationships mass spectrometry phosphoproteomics programmed cell death ligand 2 (PD-L2) programmed cell death protein 1 (PD-1) signaling networks

Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
25 12 2020
Historique:
received: 09 06 2020
revised: 10 09 2020
pubmed: 21 10 2020
medline: 26 3 2021
entrez: 20 10 2020
Statut: ppublish

Résumé

Programmed cell death protein 1 (PD-1) is a critical inhibitory receptor that limits excessive T cell responses. Cancer cells have evolved to evade these immunoregulatory mechanisms by upregulating PD-1 ligands and preventing T cell-mediated anti-tumor responses. Consequently, therapeutic blockade of PD-1 enhances T cell-mediated anti-tumor immunity, but many patients do not respond and a significant proportion develop inflammatory toxicities. To improve anti-cancer therapy, it is critical to reveal the mechanisms by which PD-1 regulates T cell responses. We performed global quantitative phosphoproteomic interrogation of PD-1 signaling in T cells. By complementing our analysis with functional validation assays, we show that PD-1 targets tyrosine phosphosites that mediate proximal T cell receptor signaling, cytoskeletal organization, and immune synapse formation. PD-1 ligation also led to differential phosphorylation of serine and threonine sites within proteins regulating T cell activation, gene expression, and protein translation.

Identifiants

pubmed: 33077516
pii: S0021-9258(17)50680-8
doi: 10.1074/jbc.RA120.014745
pmc: PMC7939457
pii:
doi:

Substances chimiques

Cytokines 0
Ligands 0
PDCD1 protein, human 0
Phosphoproteins 0
Programmed Cell Death 1 Receptor 0
Proteome 0
Receptors, Antigen, T-Cell 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18036-18050

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI125640
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150597
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA231277
Pays : United States

Informations de copyright

© 2020 Tocheva et al.

Déclaration de conflit d'intérêts

Conflict of interest—A. M. received research support from NTB Pharma. The authors declare that they have no conflicts of interest with the contents of this article.

Références

J Biol Chem. 2020 Apr 3;295(14):4372-4380
pubmed: 31882544
Annu Rev Immunol. 2011;29:665-705
pubmed: 21219180
J Allergy Clin Immunol. 2015 Feb;135(2):564-7
pubmed: 25240786
Mol Cell Biol. 2013 Aug;33(16):3091-8
pubmed: 23732914
Mol Cell Proteomics. 2008 Sep;7(9):1598-608
pubmed: 18463090
Sci Signal. 2012 Jun 26;5(230):ra46
pubmed: 22740686
Nat Rev Immunol. 2004 Apr;4(4):301-8
pubmed: 15057788
Front Immunol. 2017 Dec 11;8:1653
pubmed: 29312284
Front Immunol. 2015 Jun 26;6:310
pubmed: 26167163
Proteomics. 2015 Jan;15(2-3):500-7
pubmed: 25307156
Annu Rev Immunol. 2016 May 20;34:539-73
pubmed: 26927206
Blood. 2009 Apr 2;113(14):3198-208
pubmed: 19190244
Nat Rev Immunol. 2004 Aug;4(8):603-16
pubmed: 15286727
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Cell Rep. 2018 Apr 3;23(1):39-49
pubmed: 29617671
Mol Cell Biol. 2014 Apr;34(8):1474-85
pubmed: 24515435
Elife. 2017 Sep 26;6:
pubmed: 28949297
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Front Immunol. 2019 Mar 29;10:630
pubmed: 31001256
Immunity. 2006 Jun;24(6):741-52
pubmed: 16782030
Front Immunol. 2018 Nov 27;9:2737
pubmed: 30542345
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Science. 2017 Mar 31;355(6332):1428-1433
pubmed: 28280247
Cell. 2018 Oct 4;175(2):313-326
pubmed: 30290139
Cancer Res. 2018 Feb 1;78(3):706-717
pubmed: 29055015
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Mol Cell Biol. 2005 Nov;25(21):9543-53
pubmed: 16227604
PLoS One. 2009;4(5):e5430
pubmed: 19412549
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Cold Spring Harb Perspect Biol. 2010 Aug;2(8):a005512
pubmed: 20610546
Science. 2017 Mar 31;355(6332):1423-1427
pubmed: 28280249
Nat Immunol. 2009 Nov;10(11):1185-92
pubmed: 19783989
J Exp Med. 2012 Jun 4;209(6):1201-17
pubmed: 22641383
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nat Commun. 2017 Dec 20;8(1):2214
pubmed: 29263426
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20296-301
pubmed: 18077330
Nat Immunol. 2001 Mar;2(3):261-8
pubmed: 11224527
Blood. 2015 Jul 9;126(2):212-21
pubmed: 25979947
Biochem J. 2001 Jun 1;356(Pt 2):461-71
pubmed: 11368773
Curr Biol. 2018 Dec 3;28(23):3886-3891.e4
pubmed: 30471998
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
FEBS Lett. 2004 Sep 10;574(1-3):37-41
pubmed: 15358536

Auteurs

Anna S Tocheva (AS)

Columbia Center for Translational Immunology, Columbia University Medical Center, New York, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: anna.tocheva@mssm.edu.

Michael Peled (M)

Perlmutter Cancer Center, NYU School of Medicine, New York, New York, USA; The Institute of Pulmonary Medicine, the Chaim Sheba Medical Center, Ramat Gan, Israel.

Marianne Strazza (M)

Columbia Center for Translational Immunology, Columbia University Medical Center, New York, USA; Division of Rheumatology, Columbia University Medical Center, New York, New York, USA.

Kieran R Adam (KR)

Columbia Center for Translational Immunology, Columbia University Medical Center, New York, USA; Division of Rheumatology, Columbia University Medical Center, New York, New York, USA.

Shalom Lerrer (S)

Columbia Center for Translational Immunology, Columbia University Medical Center, New York, USA; Division of Rheumatology, Columbia University Medical Center, New York, New York, USA.

Shruti Nayak (S)

Proteomics Laboratory, NYU School of Medicine, New York, New York, USA.

Inbar Azoulay-Alfaguter (I)

Perlmutter Cancer Center, NYU School of Medicine, New York, New York, USA.

Connor J R Foster (CJR)

Perlmutter Cancer Center, NYU School of Medicine, New York, New York, USA.

Elliot A Philips (EA)

Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, New York, USA.

Benjamin G Neel (BG)

Perlmutter Cancer Center, NYU School of Medicine, New York, New York, USA.

Beatrix Ueberheide (B)

Proteomics Laboratory, NYU School of Medicine, New York, New York, USA.

Adam Mor (A)

Columbia Center for Translational Immunology, Columbia University Medical Center, New York, USA; Division of Rheumatology, Columbia University Medical Center, New York, New York, USA. Electronic address: am5121@cumc.columbia.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH